PsiOxus Therapeutics Limited To Release Study Results Of Oncolytic Vaccine Enadenotucirev In Cancer Patients
5/13/2014 8:44:44 AM
OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that two of its on-going phase I studies of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting to be held 30 May to 3 June, 2014 in Chicago, Illinois.
Help employers find you! Check out all the jobs and post your resume.
comments powered by